[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-001", "question": "A 45-year-old man with a history of migraine presents with acute onset of right-sided hemiparesis and aphasia. MRI shows restricted diffusion in the left middle cerebral artery territory, but no large vessel occlusion on angiography. Lumbar puncture reveals normal opening pressure, 5 WBCs/μL (all lymphocytes), protein 45 mg/dL, glucose 60 mg/dL, and negative oligoclonal bands. Serum testing is positive for anti-NMDA receptor antibodies. What is the most appropriate next step in management?", "options": ["Initiate intravenous thrombolysis", "Administer high-dose intravenous methylprednisolone", "Start rituximab infusion", "Perform plasmapheresis", "Administer acyclovir empirically"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests anti-NMDA receptor encephalitis mimicking stroke, and rituximab is indicated for refractory cases or as first-line in severe presentations per subspecialty guidelines. High-dose steroids are often initial, but in antibody-positive cases with stroke-like features, rituximab targets B-cell depletion more effectively. Plasmapheresis is an alternative but not superior in this context without evidence of fulminant progression.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the clinical presentation and diagnostic findings.\n\nThe patient presents with:\n- Acute onset right hemiparesis and aphasia\n- MRI showing restricted diffusion in left MCA territory (suggesting ischemia)\n- No large vessel occlusion on angiography\n- Normal CSF findings except for mild pleocytosis\n- Positive anti-NMDA receptor antibodies in serum\n\nThis presentation is consistent with autoimmune encephalitis, specifically anti-NMDA receptor encephalitis, which can present with stroke-like symptoms. The positive antibody test confirms this diagnosis.\n\nFor autoimmune encephalitis, first-line immunotherapy typically includes:\n- High-dose corticosteroids\n- IVIG\n- Plasmapheresis\n\nRituximab is generally considered second-line therapy. Thrombolysis would be inappropriate without a true stroke, and there's no indication for acyclovir as the CSF findings don't suggest viral encephalitis.\n\nGiven the acute presentation and confirmed antibody-mediated process, the most appropriate initial management would be immunotherapy with high-dose steroids.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-002", "question": "A 62-year-old woman with Parkinson's disease on levodopa/carbidopa develops sudden visual hallucinations and paranoia. She has no fever, normal vital signs, and her Unified Parkinson's Disease Rating Scale score has worsened by 15 points. CSF analysis shows 10 WBCs/μL (mononuclear), protein 55 mg/dL, and negative PCR for herpes simplex virus. What is the most likely underlying mechanism?", "options": ["Dopaminergic overstimulation in mesolimbic pathways", "Alpha-synuclein aggregation in occipital lobes", "Autoimmune encephalitis with anti-LGI1 antibodies", "Lewy body deposition in limbic structures", "Serotonergic imbalance from medication withdrawal"], "answer": "C", "answer_index": 2, "explanation": "This scenario points to anti-LGI1 encephalitis, which can mimic psychiatric decompensation in Parkinson's patients and is associated with faciobrachial dystonic seizures or hallucinations. Dopaminergic effects are common but do not explain the CSF pleocytosis. Lewy body involvement is typical in dementia with Lewy bodies but lacks the acute inflammatory CSF findings here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To determine the most likely mechanism for this patient's symptoms, I'll analyze the key clinical features:\n\n1) 62-year-old woman with Parkinson's disease on levodopa/carbidopa\n2) Sudden visual hallucinations and paranoia\n3) No fever, normal vital signs\n4) Worsened UPDRS score (15 points)\n5) CSF showing mild pleocytosis (10 WBCs/μL, mononuclear) and slightly elevated protein\n\nVisual hallucinations and paranoia in a Parkinson's patient can have several causes:\n\nOption A (Dopaminergic overstimulation): Levodopa and other dopaminergic medications can cause psychotic symptoms through overstimulation of mesolimbic dopamine pathways. This is a common side effect, especially with long-term treatment.\n\nOption B (Alpha-synuclein in occipital lobes): While alpha-synuclein aggregation occurs in Parkinson's, it typically doesn't present with sudden onset symptoms or CSF abnormalities.\n\nOption C (Anti-LGI1 autoimmune encephalitis): This would typically present with more prominent neurological symptoms like seizures and memory impairment.\n\nOption D (Lewy body deposition in limbic structures): This represents progression of underlying disease rather than a sudden change, and wouldn't explain the CSF findings.\n\nOption E (Serotonergic imbalance): There's no mention of medication withdrawal.\n\nThe mild CSF abnormalities suggest an inflammatory component, but the most common cause of hallucinations and paranoia in a treated Parkinson's patient is medication effect.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-003", "question": "A 28-year-old woman at 32 weeks gestation presents with severe pelvic pain and vaginal bleeding. Ultrasound shows a low-lying placenta with abnormal lacunae and loss of the retroplacental clear space. MRI confirms myometrial thinning and turbulent flow voids. What is the most appropriate management strategy?", "options": ["Expectant management with bed rest", "Immediate cesarean delivery", "Uterine artery embolization", "Balloon tamponade post-delivery", "Prophylactic internal iliac artery ligation"], "answer": "E", "answer_index": 4, "explanation": "This describes placenta accreta spectrum, and prophylactic internal iliac artery ligation reduces hemorrhage risk during planned cesarean hysterectomy in high-risk cases. Immediate delivery risks uncontrolled bleeding without preparation. Embolization is adjunctive but not primary in antenatal planning for accreta.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with clinical features highly suggestive of placenta accreta spectrum (PAS), specifically placenta percreta. The key findings include:\n\n- Severe pelvic pain and vaginal bleeding at 32 weeks\n- Low-lying placenta on ultrasound\n- Abnormal placental lacunae\n- Loss of retroplacental clear space\n- MRI confirmation of myometrial thinning and turbulent flow voids\n\nThese imaging findings are classic for placenta accreta spectrum, which represents abnormal placental invasion into the uterine wall. Given the severity of her presentation with active bleeding at 32 weeks, immediate delivery is indicated.\n\nFor placenta accreta spectrum, the standard of care is cesarean delivery with potential hysterectomy if needed, performed by a multidisciplinary team. Expectant management would be dangerous with active bleeding. Uterine artery embolization, balloon tamponade, and iliac artery ligation are adjunctive measures that might be used during or after delivery but are not the primary management strategy in this acute situation.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-004", "question": "A 35-year-old woman with endometriosis undergoes laparoscopic excision and develops postoperative fever, leukocytosis, and pelvic pain. CT shows a 5 cm complex adnexal mass with gas bubbles. Blood cultures are negative, but vaginal cultures grow mixed anaerobes. What is the most likely diagnosis?", "options": ["Ovarian abscess from bowel perforation", "Endometrioma superinfection", "Tubo-ovarian abscess from pelvic inflammatory disease", "Postoperative hematoma with secondary infection", "Clostridial myonecrosis of the uterus"], "answer": "A", "answer_index": 0, "explanation": "Bowel perforation during endometriosis surgery can lead to ovarian abscess with gas-forming anaerobes, explaining the imaging and cultures. Endometrioma infection is less likely without prior instrumentation. Tubo-ovarian abscess typically involves gonadal pathogens, not mixed anaerobes from bowel flora.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To determine the most likely diagnosis, I'll analyze the key clinical findings and their significance.\n\nThe patient is a 35-year-old woman with endometriosis who developed symptoms after laparoscopic excision. The key findings include:\n- Postoperative fever, leukocytosis, and pelvic pain\n- CT showing a 5 cm complex adnexal mass with gas bubbles\n- Negative blood cultures\n- Vaginal cultures growing mixed anaerobes\n\nThe presence of gas bubbles in the adnexal mass strongly suggests an infectious process involving gas-forming organisms. The mixed anaerobic growth from vaginal cultures supports this.\n\nOption A (Ovarian abscess from bowel perforation): While possible, there's no specific indication of bowel injury during surgery.\n\nOption B (Endometrioma superinfection): This is highly plausible given her history of endometriosis. The laparoscopic excision may have been for endometriomas, and residual tissue could become infected postoperatively.\n\nOption C (Tubo-ovarian abscess from PID): Typically develops from ascending infection, not immediately after surgery, and the patient has no mentioned history of PID.\n\nOption D (Postoperative hematoma with secondary infection): This is very likely given the recent surgery, the timing of symptoms, and the presence of mixed anaerobes.\n\nOption E (Clostridial myonecrosis): This is a rapidly progressive, life-threatening condition that would present more dramatically.\n\nBased on the clinical scenario, the most likely diagnosis is a postoperative hematoma that has become secondarily infected with anaerobic bacteria.\n\nThe answer is (D)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-005", "question": "A 58-year-old man with hypertrophic cardiomyopathy presents with syncope. Echocardiogram shows left ventricular outflow tract gradient of 80 mmHg at rest, increasing to 120 mmHg with Valsalva. He is on beta-blockers but remains symptomatic. Genetic testing reveals a MYH7 mutation. What is the most appropriate next intervention?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantable cardioverter-defibrillator placement", "Dual-chamber pacing", "Mavacamten therapy"], "answer": "E", "answer_index": 4, "explanation": "Mavacamten, a cardiac myosin inhibitor, is indicated for symptomatic obstructive hypertrophic cardiomyopathy refractory to beta-blockers, targeting the underlying MYH7-related hypercontractility. Alcohol ablation and myectomy are invasive options for severe cases, but mavacamten offers medical management first. ICD is for arrhythmia risk, not outflow obstruction.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most appropriate next intervention for this patient with hypertrophic cardiomyopathy (HCM), I'll analyze the key clinical features and treatment options.\n\nThe patient has:\n- Symptomatic HCM with syncope despite beta-blocker therapy\n- Severe LVOT obstruction (80 mmHg at rest, 120 mmHg with Valsalva)\n- MYH7 mutation confirmed by genetic testing\n\nFor symptomatic obstructive HCM with significant LVOT gradients (>50 mmHg) that remains symptomatic despite optimal medical therapy, septal reduction therapy is indicated.\n\nThe two main septal reduction options are:\n- Surgical myectomy: Considered the gold standard with excellent long-term outcomes\n- Alcohol septal ablation: Less invasive but with higher risk of conduction abnormalities and less complete gradient reduction\n\nRegarding the other options:\n- ICD placement would be indicated for primary prevention in high-risk patients, but doesn't address the LVOT obstruction\n- Dual-chamber pacing has limited efficacy for LVOT obstruction\n- Mavacamten is a newer cardiac myosin inhibitor approved for obstructive HCM, but typically used when septal reduction therapy is not appropriate or declined\n\nGiven the severe obstruction and failure of medical therapy, septal reduction therapy is indicated, with surgical myectomy being the preferred option in a patient who can tolerate surgery.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-006", "question": "A 70-year-old woman with atrial fibrillation on apixaban develops acute chest pain. Coronary angiography shows spontaneous coronary artery dissection in the left anterior descending artery. She is hemodynamically stable with TIMI 3 flow. What is the most appropriate management?", "options": ["Percutaneous coronary intervention with stenting", "Continuation of apixaban with close monitoring", "Switch to dual antiplatelet therapy", "Surgical bypass grafting", "Conservative management with beta-blockers"], "answer": "E", "answer_index": 4, "explanation": "Conservative management with beta-blockers is preferred for stable spontaneous coronary artery dissection with preserved flow, as it promotes healing and reduces shear stress. Anticoagulation like apixaban increases bleeding risk in dissection. PCI is reserved for unstable cases due to high complication rates.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "To answer this question, I need to consider the management of spontaneous coronary artery dissection (SCAD) in the context of a patient with atrial fibrillation on anticoagulation.\n\nFor SCAD, the current evidence favors conservative management in stable patients with preserved coronary flow (TIMI 3), as this patient has. Invasive interventions like PCI with stenting (option A) can actually worsen the dissection and have higher complication rates in SCAD compared to atherosclerotic disease.\n\nThe patient is already on apixaban for atrial fibrillation. Continuing this medication (option B) would increase bleeding risk without clear benefit for the SCAD.\n\nSwitching to dual antiplatelet therapy (option C) would address the coronary issue but leave the patient without adequate anticoagulation for atrial fibrillation.\n\nSurgical bypass (option D) would be overly aggressive for a stable SCAD with preserved flow.\n\nConservative management with beta-blockers (option E) is the standard of care for stable SCAD patients with preserved flow. Beta-blockers reduce arterial wall stress and heart rate, which can help prevent extension of the dissection while allowing for spontaneous healing.\n\nThe answer is (E)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-007", "question": "A 40-year-old man returning from West Africa presents with fever, myalgias, and petechial rash. Labs show thrombocytopenia, elevated liver enzymes, and PCR positive for Lassa virus. He develops acute kidney injury with oliguria. What is the most appropriate therapeutic intervention?", "options": ["Intravenous ribavirin", "Supportive care with hemodialysis", "Convalescent plasma transfusion", "Favipiravir administration", "Monoclonal antibody therapy"], "answer": "A", "answer_index": 0, "explanation": "Intravenous ribavirin is the mainstay for Lassa fever, reducing mortality especially when initiated early, and it addresses viremia in cases with renal involvement. Supportive care is essential but not sufficient alone. Favipiravir is investigational and not standard for Lassa.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To address this case of Lassa fever, I'll evaluate each therapeutic option:\n\nA. Intravenous ribavirin - Ribavirin is the established antiviral treatment for Lassa fever, particularly effective when administered early in the disease course. It has been shown to reduce mortality, especially when given within the first 6 days of illness.\n\nB. Supportive care with hemodialysis - While supportive care is important in Lassa fever management and hemodialysis may be needed for the acute kidney injury, this alone is not the most appropriate primary intervention when a specific antiviral therapy is available.\n\nC. Convalescent plasma transfusion - Not established as standard therapy for Lassa fever and has limited evidence supporting its efficacy.\n\nD. Favipiravir - While showing promise in animal models, it is not the first-line treatment for Lassa fever in humans.\n\nE. Monoclonal antibody therapy - Not currently established as standard treatment for Lassa fever.\n\nFor a confirmed case of Lassa fever with complications including kidney injury, the most appropriate specific intervention would be intravenous ribavirin, which should be initiated promptly, along with appropriate supportive care.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-008", "question": "A 55-year-old immunocompromised patient with lung transplant develops dyspnea and ground-glass opacities on CT. Bronchoalveolar lavage PCR is positive for Pneumocystis jirovecii, but serum beta-D-glucan is negative. He is on trimethoprim-sulfamethoxazole prophylaxis. What explains the breakthrough infection?", "options": ["Dihydropteroate synthase gene mutation", "Non-adherence to prophylaxis", "Concurrent cytomegalovirus co-infection", "Inadequate dosing in obesity", "Atovaquone cross-resistance"], "answer": "A", "answer_index": 0, "explanation": "Mutations in the dihydropteroate synthase gene confer resistance to sulfamethoxazole in Pneumocystis, leading to breakthrough despite prophylaxis in immunocompromised hosts. Non-adherence is common but less likely with negative beta-D-glucan suggesting low burden. CMV co-infection exacerbates but does not cause resistance.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to analyze the scenario of an immunocompromised lung transplant patient with breakthrough Pneumocystis jirovecii pneumonia (PJP) despite being on TMP-SMX prophylaxis.\n\nKey considerations:\n- Patient is on TMP-SMX prophylaxis but still developed PJP\n- PCR is positive but beta-D-glucan is negative\n- Patient is immunocompromised due to lung transplant\n\nAnalyzing each option:\n\nA. Dihydropteroate synthase gene mutation - This is a known mechanism of resistance to TMP-SMX in Pneumocystis jirovecii. Mutations in the DHPS gene can lead to resistance to sulfonamides, which would explain why prophylaxis failed despite adherence.\n\nB. Non-adherence to prophylaxis - While possible, there's no specific indication of non-adherence in the scenario.\n\nC. Concurrent CMV co-infection - While CMV can worsen immunosuppression, it doesn't directly explain resistance to TMP-SMX.\n\nD. Inadequate dosing in obesity - No information about the patient's weight is provided, making this speculative.\n\nE. Atovaquone cross-resistance - Atovaquone has a different mechanism of action than TMP-SMX, and cross-resistance is not typically observed.\n\nThe most likely explanation for breakthrough infection despite prophylaxis is resistance due to mutations in the DHPS gene, which is the target of sulfonamides.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-009", "question": "A 50-year-old woman with rheumatoid arthritis on tofacitinib presents with symmetric polyarthritis flare, fever, and macular rash. Labs show pancytopenia, ferritin 10,000 ng/mL, triglycerides 400 mg/dL, and fibrinogen 100 mg/dL. Bone marrow biopsy reveals hemophagocytosis. What is the most appropriate initial treatment?", "options": ["High-dose glucocorticoids", "Cyclosporine A", "Anakinra", "Etoposide-based chemotherapy", "Intravenous immunoglobulin"], "answer": "C", "answer_index": 2, "explanation": "Anakinra, an IL-1 inhibitor, is effective for macrophage activation syndrome in rheumatoid arthritis, targeting cytokine storm and improving survival without broad immunosuppression. Glucocorticoids are adjunctive but insufficient alone in JAK inhibitor-associated cases. Etoposide is for refractory HLH but not first-line here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with clinical features consistent with hemophagocytic lymphohistiocytosis (HLH), which is evidenced by:\n- Fever\n- Pancytopenia\n- Extremely high ferritin (10,000 ng/mL)\n- Elevated triglycerides (400 mg/dL)\n- Low fibrinogen (100 mg/dL)\n- Hemophagocytosis on bone marrow biopsy\n\nThe patient has secondary HLH (also called macrophage activation syndrome when associated with rheumatic diseases) in the setting of rheumatoid arthritis and JAK inhibitor therapy with tofacitinib.\n\nFor initial treatment of HLH/macrophage activation syndrome, high-dose glucocorticoids are the first-line therapy to rapidly suppress the hyperinflammatory state. This is typically followed by or combined with other immunosuppressive agents if there is inadequate response.\n\nWhile cyclosporine, anakinra, etoposide, and IVIG may all have roles in HLH management, high-dose glucocorticoids represent the most appropriate initial treatment for this patient with rheumatoid arthritis-associated HLH.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-010", "question": "A 65-year-old man with giant cell arteritis on prednisone taper develops jaw claudication and vision loss. ESR is 80 mm/hr, and temporal artery biopsy is negative. CTA shows aortic arch involvement. What is the most appropriate escalation in therapy?", "options": ["Increase prednisone to 60 mg daily", "Add methotrexate", "Initiate tocilizumab", "Start cyclophosphamide", "Perform temporal artery ultrasound"], "answer": "C", "answer_index": 2, "explanation": "Tocilizumab, an IL-6 inhibitor, is indicated for refractory giant cell arteritis with large vessel involvement, reducing relapse and steroid requirements. High-dose prednisone is initial but inadequate for escalation in biopsy-negative cases. Methotrexate is steroid-sparing but less effective for vision-threatening disease.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to consider the clinical scenario of a patient with giant cell arteritis (GCA) who is experiencing worsening symptoms despite being on prednisone.\n\nThe patient has:\n- Known GCA on prednisone taper\n- New jaw claudication and vision loss (indicating disease progression)\n- Elevated ESR (80 mm/hr) suggesting active inflammation\n- Negative temporal artery biopsy (which can occur in 10-15% of GCA cases)\n- CTA showing aortic arch involvement (large-vessel GCA)\n\nThis represents a severe flare with vision involvement, which is a medical emergency requiring immediate treatment escalation.\n\nFor severe GCA with visual symptoms:\n- High-dose glucocorticoids are the first-line treatment\n- Tocilizumab has been shown in clinical trials (GiACTA trial) to be effective as a steroid-sparing agent for GCA\n- Methotrexate has modest efficacy as a steroid-sparing agent\n- Cyclophosphamide is rarely used in GCA and reserved for refractory cases\n- Temporal artery ultrasound would be diagnostic, not therapeutic\n\nGiven the vision loss (a serious complication) and evidence of active disease despite prednisone treatment, the most appropriate next step is to increase the prednisone dose to control the inflammation quickly, particularly to prevent further vision loss.\n\nThe answer is (A)"}]